PubRank

David Oscier

Author PubWeight™ 71.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010 7.96
2 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005 6.05
3 Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011 4.37
4 Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005 4.27
5 Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009 3.69
6 JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009 3.21
7 Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003 2.54
8 Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010 2.45
9 Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006 2.29
10 ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005 1.93
11 ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2005 1.91
12 Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2002 1.85
13 Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007 1.82
14 Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011 1.71
15 Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood 2013 1.68
16 Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2005 1.64
17 Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 2008 1.59
18 A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003 1.41
19 Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012 1.36
20 Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012 1.35
21 DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009 1.22
22 Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010 1.21
23 The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010 1.16
24 Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013 1.06
25 Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OS. Gene 2003 1.05
26 Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol 2008 1.05
27 Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol 2014 1.05
28 Exome sequence read depth methods for identifying copy number changes. Brief Bioinform 2014 1.00
29 High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol 2012 1.00
30 The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer 2008 0.96
31 Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2011 0.96
32 ZAP-70 in B cell malignancies. Leuk Lymphoma 2005 0.92
33 CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. Haematologica 2012 0.87
34 Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. Immunogenetics 2014 0.83
35 Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. J Cell Mol Med 2012 0.82
36 The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014 0.81
37 Capillary electrophoresis-laser induced fluorescence analysis of endogenous damage in mitochondrial and genomic DNA. Electrophoresis 2005 0.81
38 Splenic marginal-zone lymphoma: ontogeny and genetics. Leuk Lymphoma 2014 0.80
39 A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia. Leuk Res 2011 0.75
40 History revisited... Br J Haematol 2003 0.75